John L. McClellan Memorial Veterans Hospital, Little Rock, AR

Is John L. McClellan Memorial Veterans Hospital registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does John L. McClellan Memorial Veterans Hospital hold a Arkansas pharmacy license?

State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026.

Has John L. McClellan Memorial Veterans Hospital had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (May 12, 2025) for John L. McClellan Memorial Veterans Hospital. State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
John L. McClellan Memorial Veterans Hospital
Location
Little Rock, AR
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
May 12, 2025
FDA Data Dashboard inspections
1 inspection: 1 NAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 7 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as John L. McClellan Memorial Veterans Hospital, a 503A facility, with 2 dated actions.

Document
May 12, 2025FMD-145 letterFMD-145 Letter Issued 05/12/2025Not linked by FDA
Jan 23, 2020Amended Form 483Amended 483 Issued 01/23/2020FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists John L. McClellan Memorial Veterans Hospital, Little Rock, AR (FEI number 3013521045), matched to this page by exact name, city and state. It lists 1 inspection: 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Dec 13, 2024No Action Indicated (NAI)Drug Quality Assurance (Drugs)30135210451259377

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection dated Jan 23, 2020 by FDA (dates on the form not read): 7 observations

Firm on the cover
John L. Mc Clellan Memorial Veterans Hospital, 4300 W. 7th St. Rm 1D100, Little Rock, AR 722 05-5446
FEI number
3013521045
Establishment type on the cover
Pro ducer of S ter ile Drug Produ cts
FDA district office on the cover
U.S. Food and Drug Admini stration 404 o North Central Expressway, Suite 300 Dallas, Texas 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically,

A. On 13 January 2020, we observed your pharmacist use non-sterile <Redacted B4> during routine cleaning of the interior area of your biological safety cabinet ( Classified IS0-5), located in the Hazardous Room of your <Redacted B4> mobile unit, where aseptic operations occur for sterile chemotherapeutic agents.

B. Your firm uses non-sterile bactericidal <Redacted B4> cleaning solution during routine <Readcted B4> cleanings of your classified areas where aseptic operations are performed, for example, but not limited to, the interior surfaces of ISO-5 equipment:

1. <Redacted B4> IS0-5 Classified Biological Safety Cabinets (BSCs), located in your firm's <Redacted B4> Mobile Unit Hazardous Area;

< Read cted B4> IS0-5 Classified Laminar Air Flow Hoods (LAFHs), located in your firm 's <Redacted B4> Mobile Unit Non-Hazardous Area;

3. <Redacted B4> (2) IS0-5 Classified LAFHs, located in your firm's Segregated Compounding Area (SCA) on the ground floor of your in-patient pharmacy.

C. ...

Read the full 483 (PDF on fda.gov)

Observation 2

IY ou did not make adequate product evaluation and take remedial action where actionable microbial contamination was fot.md o be present in an area adjacent to the ISO 5 classified aseptic processing area during aseptic production.

Specifically, eleven (11) colony forming units (cfus) were identified in your firm's Hazardous Buffer Room (IS0-7 Classified) during viable air sampling conducted on 18 September 2019 at location "Trailer.,j Hazard Room". The firm's Sample Analysis Results, dated 23 September 2019, documents the colony identifications are: Gram-positive rods; micrococcu5; staphylococcu5 colagulase (-); and other fungi. According to your firm 's sampling plan and the firm's Sample Analysis Results report, your firm has not resampled in this location ("Trailer: Hazard Room") ensuring the area is acceptable to continue aseptic operations prior to this FDA inspection. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Equipment was not disinfected prior to entering the aseptic processing areas.

Specifically, on 01/17/2020, your Environmental Management Service (EMS) Supervisor, who conducts periodic routine cleanings of your firm's cleanrooms, stated they do not disinfect the <Redacted B4> prior to entering your firm's cleanrooms (ISO-8 and ISO-7 Classified Areas). This cleaning equipment is stored in an unclassified area and are used on a <Redacted B4> basis.

=nu _ .. _

Observation 4

IY our facility design allowed the influx of poor-quality air into a higher classified area.

Specifically,

A

On 1/13/2020, we observed two (2) flexible hoses which are connected to your <Redacted B4> Mobile Unit and lead to a street water drain. The purpose of these hoses is to drain the <Redacted B4> from the sinks located in the <Redacted B4> Mobile Unit (Hazardou-; Area: ISO-7 Classified Anteroom; and the Non-Hazardous: ISO-8 Classified Anteroom). The hoses are unprotected and exposed to the outside environment and appear to be cracked and discolored. Your finn has not provided any supporting documentation to prevent the ingress of vermin or outside unfiltered, less clean air.

B. On 01/22/2020, we observed your return air vents, located in your <Redacted B4> Mobile Unit in the:

Hazardous Buffer Room (ISO-7 Classified) where chemotherapeutic agents are aseptically processed were partially blocked by objects such as, but not limited to portable bins; stainless steel tables; and storage shelving; ...

Read the full 483 (PDF on fda.gov)

Observation 5

Personnel engaged in aseptic processing were observed with exposed face, neck, and ankles.

Specifically, on 01/13/2020 and 01/22/2020, we observed your pharmacy technician, who was engaged in aseptic operations of Carboplatin 520 mg and Doxorubicin 105 mg, respectively, with exposed face, neck, and ankles in the ISO-7 Classified Area of the <Redacted B4> Mobile Unit Hazardous Compounding Area.

In addition, your pharmacy technicians don non-sterile gowns, bouffant, facemask, and booties.

Observation 6

Personnel did not disinfect and change gloves frequently enough to prevent contamination.

observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representalive(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

Specifically, on 01/17/2020, your Environmental Management Service (EMS) Supervisor, who conducts periodic routine cleanings of your firm's cleanrooms, stated they do not sanitize their hands or change their gloves when moving from an area of cleaner air (ISO-7 Classified -Non-Hazardous Buffer) to an area of less cleaner air (ISO-8 Classified -Non-Hazardous Anteroom) and back to an area of cleaner air (ISO-7 Classified -Non-Hazardous Buffer) during routine <Redacted B4> cleanings of your firm 's cleanrooms, where sterile drug products are produced.

Observation 7

You had inadequate HEPA filter coverage and airflow over the area to which sterile product was exposed.

Specifically, your firm's air flow patterns performed 08 July 2019, by vendor <Redacted B4> and as part of your firm's <Redacted B4> certifications are inadequate.

A

The smoke studies conducted wider dynamic conditions did not generate smoke in all areas where aseptic operations were performed to verify unidirectional airflow, for example, but are not limited to: the movement of materials into the BSC (ISO-5 Classified); removing vials and syringes from outer packaging within the BSC (ISO-5 Classified); cleaning of vials with <Redacted B4>. In addition, the smoke study did not capture your most challenging aseptic operation.

B. The smoke studies performed at the door from the Hazardous Anteroom (ISO-7 Classified), which is under positive pressure, into the Hazardous Buffer Room (ISO-7 Classified), which I under negative pressure, did not demonstrate the Hazardous Buffer Room (ISO-7 Classified) is maintained under negative pressure.

C. ...

Read the full 483 (PDF on fda.gov)

State board of pharmacy records

State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.